Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Peter R. Galle, Richard S. Finn, Shukui Qin, Masafumi Ikeda, Andrew X. Zhu, Tae-You Kim, Masatoshi Kudo, Valeriy Vladimirovich Breder, Philippe Merle, Ahmed Omar Kaseb, Daneng Li, Sohail Mulla, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Juan Liu, Chen Huang, Ho Yeong Lim, Ann-Lii Cheng, Michel Ducreux
Institutions: University Medical Center of the Johannes Gutenberg University Mainz, University of California, Los Angeles, National Cancer Center Hospital East, Massachusetts General Hospital, Seoul National University, Seoul National University Hospital, Kindai University, Russian Cancer Research Center NN Blokhin, Ministry of Health of the Russian Federation, Université de Lyon, The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, Genentech, Roche (China), Samsung Medical Center, National Taiwan University Hospital, Institut Gustave Roussy
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3005136653